VU 0360172 hydrochloridePositive allosteric modulator at mGlu5 CAS# 1309976-62-2 |
2D Structure
- FLAG tag Peptide
Catalog No.:BCC2562
CAS No.:98849-88-8
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 1309976-62-2 | SDF | Download SDF |
PubChem ID | 53384852 | Appearance | Powder |
Formula | C18H16ClFN2O | M.Wt | 330.78 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 50 mM in DMSO and to 25 mM in ethanol | ||
Chemical Name | N-cyclobutyl-6-[2-(3-fluorophenyl)ethynyl]pyridine-3-carboxamide;hydrochloride | ||
SMILES | C1CC(C1)NC(=O)C2=CN=C(C=C2)C#CC3=CC(=CC=C3)F.Cl | ||
Standard InChIKey | NBGAPTWZQXSEAA-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C18H15FN2O.ClH/c19-15-4-1-3-13(11-15)7-9-16-10-8-14(12-20-16)18(22)21-17-5-2-6-17;/h1,3-4,8,10-12,17H,2,5-6H2,(H,21,22);1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Positive allosteric modulator of mGlu5 receptors (EC50 = 16 nM; Ki = 195 nM). Selective for mGlu5; displays no significant activity at mGlu1, mGlu2 or mGlu4 receptors. Exhibits antipsychotic-like activity in a rodent model. Also reduces spontaneous spike and wave discharges without affecting motor behaviour in a rat model of absence epilepsy. |
VU 0360172 hydrochloride Dilution Calculator
VU 0360172 hydrochloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.0232 mL | 15.1158 mL | 30.2316 mL | 60.4631 mL | 75.5789 mL |
5 mM | 0.6046 mL | 3.0232 mL | 6.0463 mL | 12.0926 mL | 15.1158 mL |
10 mM | 0.3023 mL | 1.5116 mL | 3.0232 mL | 6.0463 mL | 7.5579 mL |
50 mM | 0.0605 mL | 0.3023 mL | 0.6046 mL | 1.2093 mL | 1.5116 mL |
100 mM | 0.0302 mL | 0.1512 mL | 0.3023 mL | 0.6046 mL | 0.7558 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 15-Methoxymkapwanin
Catalog No.:BCN6498
CAS No.:1309920-99-7
- MRS 4062 triethylammonium salt
Catalog No.:BCC6134
CAS No.:1309871-50-8
- Sephin1
Catalog No.:BCC3980
CAS No.:13098-73-2
- (±)-CPSI 1306
Catalog No.:BCC6161
CAS No.:1309793-47-2
- H 89 2HCl
Catalog No.:BCC4997
CAS No.:130964-39-5
- Marumoside A
Catalog No.:BCN7702
CAS No.:1309604-34-9
- Wittifuran X
Catalog No.:BCN4794
CAS No.:1309478-07-6
- K145
Catalog No.:BCC4305
CAS No.:1309444-75-4
- GPR40 Activator 1
Catalog No.:BCC4125
CAS No.:1309435-60-6
- Cerberic acid B
Catalog No.:BCN4715
CAS No.:1309362-77-3
- CX-4945 sodium salt
Catalog No.:BCC5586
CAS No.:1309357-15-0
- Entacapone
Catalog No.:BCC2217
CAS No.:130929-57-6
- alpha-Yohimbine
Catalog No.:BCN6166
CAS No.:131-03-3
- Dimethyl phthalate
Catalog No.:BCN6167
CAS No.:131-11-3
- Pimpinellin
Catalog No.:BCN6168
CAS No.:131-12-4
- N-Acetylneuraminic acid
Catalog No.:BCN2204
CAS No.:131-48-6
- Oxybenzone
Catalog No.:BCC5445
CAS No.:131-57-7
- Meptyldinocap
Catalog No.:BCC5468
CAS No.:131-72-6
- 8-Epiloganic acid
Catalog No.:BCC8956
CAS No.:82509-41-9
- Boldenone undecylenate
Catalog No.:BCC8896
CAS No.:13103-34-9
- GNF179 Metabolite
Catalog No.:BCC5176
CAS No.:1310455-86-7
- NB-598
Catalog No.:BCC1786
CAS No.:131060-14-5
- Tubastatin A HCl
Catalog No.:BCC3877
CAS No.:1310693-92-5
- NVP-BGJ398 phosphate
Catalog No.:BCC1814
CAS No.:1310746-10-1
Potentiation of mGlu5 receptors with the novel enhancer, VU0360172, reduces spontaneous absence seizures in WAG/Rij rats.[Pubmed:22705340]
Neuropharmacology. 2013 Mar;66:330-8.
Absence epilepsy is generated by the cortico-thalamo-cortical network, which undergoes a finely tuned regulation by metabotropic glutamate (mGlu) receptors. We have shown previously that potentiation of mGlu1 receptors reduces spontaneous occurring spike and wave discharges (SWDs) in the WAG/Rij rat model of absence epilepsy, whereas activation of mGlu2/3 and mGlu4 receptors produces the opposite effect. Here, we have extended the study to mGlu5 receptors, which are known to be highly expressed within the cortico-thalamo-cortical network. We used presymptomatic and symptomatic WAG/Rij rats and aged-matched ACI rats. WAG/Rij rats showed a reduction in the mGlu5 receptor protein levels and in the mGlu5-receptor mediated stimulation of polyphosphoinositide hydrolysis in the ventrobasal thalamus, whereas the expression of mGlu5 receptors was increased in the somatosensory cortex. Interestingly, these changes preceded the onset of the epileptic phenotype, being already visible in pre-symptomatic WAG/Rij rats. SWDs in symptomatic WAG/Rij rats were not influenced by pharmacological blockade of mGlu5 receptors with MTEP (10 or 30 mg/kg, i.p.), but were significantly decreased by mGlu5 receptor potentiation with the novel enhancer, VU0360172 (3 or 10 mg/kg, s.c.), without affecting motor behaviour. The effect of VU0360172 was prevented by co-treatment with MTEP. These findings suggest that changes in mGlu5 receptors might lie at the core of the absence-seizure prone phenotype of WAG/Rij rats, and that mGlu5 receptor enhancers are potential candidates to the treatment of absence epilepsy. This article is part of a Special Issue entitled 'Metabotropic Glutamate Receptors'.
Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity.[Pubmed:20923853]
Mol Pharmacol. 2010 Dec;78(6):1105-23.
Modulators of metabotropic glutamate receptor subtype 5 (mGluR5) may provide novel treatments for multiple central nervous system (CNS) disorders, including anxiety and schizophrenia. Although compounds have been developed to better understand the physiological roles of mGluR5 and potential usefulness for the treatment of these disorders, there are limitations in the tools available, including poor selectivity, low potency, and limited solubility. To address these issues, we developed an innovative assay that allows simultaneous screening for mGluR5 agonists, antagonists, and potentiators. We identified multiple scaffolds that possess diverse modes of activity at mGluR5, including both positive and negative allosteric modulators (PAMs and NAMs, respectively). 3-Fluoro-5-(3-(pyridine-2-yl)-1,2,4-oxadiazol-5-yl)benzonitrile (VU0285683) was developed as a novel selective mGluR5 NAM with high affinity for the 2-methyl-6-(phenylethynyl)-pyridine (MPEP) binding site. VU0285683 had anxiolytic-like activity in two rodent models for anxiety but did not potentiate phencyclidine-induced hyperlocomotor activity. (4-Hydroxypiperidin-1-yl)(4-phenylethynyl)phenyl)methanone (VU0092273) was identified as a novel mGluR5 PAM that also binds to the MPEP site. VU0092273 was chemically optimized to an orally active analog, N-cyclobutyl-6-((3-fluorophenyl)ethynyl)nicotinamide hydrochloride (VU0360172), which is selective for mGluR5. This novel mGluR5 PAM produced a dose-dependent reversal of amphetamine-induced hyperlocomotion, a rodent model predictive of antipsychotic activity. Discovery of structurally and functionally diverse allosteric modulators of mGluR5 that demonstrate in vivo efficacy in rodent models of anxiety and antipsychotic activity provide further support for the tremendous diversity of chemical scaffolds and modes of efficacy of mGluR5 ligands. In addition, these studies provide strong support for the hypothesis that multiple structurally distinct mGluR5 modulators have robust activity in animal models that predict efficacy in the treatment of CNS disorders.